- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02653391
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) (SPIFD-101)
August 20, 2021 updated by: Stealth BioTherapeutics Inc.
Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema.
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a Phase 1/2 trial in two parts.
Part A is a prospective, randomized, double-masked, vehicle controlled, paired-eye study in approximately 16 subjects to evaluate safety, tolerability and efficacy of elamipretide 1.0% topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.
Part B is a prospective, randomized double-masked, vehicle controlled study in approximately 11 subjects to evaluate safety, tolerability, and efficacy of elamipretide 3.0% topical ophthalmic solution in patients with FCED presenting with mild to moderate corneal edema.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Edgewood, Kentucky, United States, 41017
- Cincinnati Eye Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults ≥18 years old at the time of Screening Visit
- Diagnosis of FCED OU (both eyes) based on clinical and ophthalmic test findings
- Clinical evidence of corneal edema OU diagnosed with FCED, including one or more of the following signs: corneal epithelial microcysts, corneal epithelial bullae, stromal folds, or stromal haze
- Central corneal thickness of 550 μm to 700 μm (inclusive) in at least one eye diagnosed with FCED, as measured by ultrasonic pachymetry at the time of Screening Visit and Baseline Visit
- Best-corrected distance visual acuity (BCVA) of 20/25 to 20/320 (inclusive) at the time of Screening Visit and Baseline Visit OU
- Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the informed consent form (ICF) until after the last study
- Able to give informed consent and willing to comply with all study visits and examinations
- Part B only: The presence of central endothelium, as determined by the investigator, with an area of contiguous endothelial cells within 1 mm of the central cornea as measured by confocal laser scanning microscopy (CLSM) or specular microscopy at the time of Screening Visit
Exclusion Criteria:
- Corneal findings of any type (including, but not limited to, stromal haze or stromal scarring), in either eye, that, based on investigator's assessment, limit the probability of visual improvement after corneal deturgescence
- Any ocular pathology requiring treatment with topical ophthalmic drops, with the exception of glaucoma or ocular hypertension
- Use of topical hypertonic saline drops for 3 days prior to Screening and throughout the duration of the study
- History of corneal disease (other than FCED) or corneal surgery in either eye
- Current use or likely need for the use of contact lens at any time during the study
- History of previous corneal or anterior segment surgery such as LASIK, photorefractive keratectomy, endothelial keratoplasty, penetrating keratoplasty cataract surgery or glaucoma surgery.
- Any disease or medical condition that in the opinion of the investigator would prevent the subject from participating in the study or might confound study results
- Participation in other investigational drug or device clinical trials within 30 days prior to enrollment, or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion
- Women who are pregnant or lactating
- Part B only: Participation in Part A of SPIFD-101
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)
Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
|
Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
Other Names:
|
Experimental: Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)
Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
|
Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
Other Names:
|
Placebo Comparator: Placebo A
Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
|
Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
|
Placebo Comparator: Part B Placebo
Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
|
Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of Ocular TEAEs.
Time Frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
|
The incidence and severity of ocular treatment emergent adverse events (TEAEs)
|
Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
|
The Incidence and Severity of Systemic Adverse Events
Time Frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
|
The incidence and severity of systemic treatment emergent adverse events (TEAEs)
|
Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part A
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Number of participants who had a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part A. Part B is reported as separate outcome since unit of measure is number of eyes.
|
Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part B
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Number of eyes with a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part B. Part A is reported as separate outcome.
|
Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Intraocular Pressure (IOP) for Part A
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12
|
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part A
|
Baseline, Week 1, Week 4, Week 8, Week 12
|
Change From Baseline in Intraocular Pressure (IOP) for Part B
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit
|
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part B. Part A is reported separately.
|
Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Central Corneal Thickness by Visit Part A as Measured by Pachymetry for Part A
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline in Central Corneal Thickness by Visit as measured by Pachymetry for Part A. Part B is reported as a separate outcome measure.
|
Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
|
Central Corneal Thickness Part B
Time Frame: Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit
|
Central Corneal Thickness: by-subject data as measured by Pachymetry and Pentacam.
Part A is reported as a separate outcome measure.
|
Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit
|
Change From Baseline Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A
Time Frame: Baseline, Week 1, 4, 8, and 12
|
Change From Baseline in Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium.
Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells.
Histologically, healthy corneal cells initially have a hexagonal shape.
As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell.
This, in turn, causes the remaining cells to lose their hexagonal shape.
Assessments were performed using the flex center and full auto methods for Part A and data from the flex center method was summarized.
The flex center method was used for Part B. The percent of Part B is entered as a separate outcome measure.
A decrease from baseline in % cell hexagonality means worse outcome, a increase from baseline means better outcome.
|
Baseline, Week 1, 4, 8, and 12
|
Corneal Endothelial Cell Hexagonality Part B
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit
|
Corneal Endothelial Cell Hexagonality in Percentage by-subject data: Part B. Data was only listed in weeks where images were good enough quality to quantify.
Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium.
Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells.
Histologically, healthy corneal cells initially have a hexagonal shape.
As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell.
This, in turn, causes the remaining cells to lose their hexagonal shape.
The flex center method was used for Part B. A decrease in percent of cell hexagonality from baseline means worse outcome, an increase from baseline means better outcome.
|
Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit
|
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale for Part A.
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16
|
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit.
ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart.
Minimum score of zero, maximum score of 100.
Change from baseline: a more negative score is worse outcome, a more positive score is better outcome.
A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Part B was listed separately.
|
Baseline, Weeks 1, 4, 8, 12, and 16
|
Best Corrected Visual Acuity (BCVA) Score Using ETDRS Scale for Part B
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16
|
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit.
ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart.
Minimum score of zero, maximum score of 100.
Change from baseline: a more negative score is worse outcome, a more positive score is better outcome.
A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
|
Baseline, Weeks 1, 4, 8, 12, and 16
|
Change From Baseline in Endothelial Cell Density Over All 12 Weeks for Part A
Time Frame: Baseline, Weeks 1, 4, 8, and 12
|
Change From Baseline in Endothelial Cell Counts, or density (Counts/mm^2) over all 12 weeks for Part A. Part B is entered as a separate outcome measure.
|
Baseline, Weeks 1, 4, 8, and 12
|
Corneal Endothelial Cell Density Part B
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16.
|
Corneal Endothelial Cell Density: Part B, By-subject data for all time points where images were readable.
For all time points where there were "Poor Quality Images" or "too few cells to register", there were no data available, and these were not listed below.
|
Baseline, Weeks 1, 4, 8, 12, and 16.
|
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks for Part A
Time Frame: Baseline, Week 12
|
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks.
Coefficient of variation (CV) is Standard deviation (SD) of cell area divided by the mean cell area of endothelial cell analyzed.
CV represents the coefficient, or degree, of variation in the sizes of the endothelial cells (polymegethism).
By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring.
The more variation, the worse the outcome.
Part B is is entered as a separate outcome measure.
|
Baseline, Week 12
|
Coefficient of Variation (CoV) Part B
Time Frame: Baseline, Weeks 1, 4, 8,12, and 16
|
Part B, By-subject data for all time points where images were readable.
For all time points where there were "Poor Quality Images" or "too few cells to register" there were no data available.
CoV represents the coefficient, or degree, of variation in the sizes of the endothelial cells.
By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring.
A CoV less than 40 is normal.
|
Baseline, Weeks 1, 4, 8,12, and 16
|
Change From Baseline in Corneal Area Affected by Microcysts for Part A
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16
|
Change from Baseline in corneal area affected by microcysts by visit for Part A.
|
Baseline, Weeks 1, 4, 8, 12, and 16
|
Corneal Area Affected by Microcysts: Part B
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit
|
Corneal area affected by microcysts: by-subject data for Part B. No microcysts were present for any timepoints.
|
Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit
|
Change From Baseline in Corneal Bullae for Part A.
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16
|
Count of participants in number, size and location of bullae by treatment.
Part B is listed separately.
|
Baseline, Week 1, Week 4, Week 8, Week 12, Week 16
|
Corneal Bullae: Part B
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
|
Number, size and location of Corneal bullae: By-subject data: Part B.
|
Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
|
Change From Baseline in Severity of Corneal Stromal Folds for Part A
Time Frame: Baseline, Weeks 1, 4, 8, 12, and 16
|
Change from baseline in severity of corneal stromal folds by visit.
Descriptive assessment made by Investigator; severity is not assessed using a scale.
|
Baseline, Weeks 1, 4, 8, 12, and 16
|
Severity of Corneal Stromal Folds:Part B
Time Frame: Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit
|
Severity of corneal stromal folds by-subject data by visit.
Descriptive assessment made by Investigator in the following categories: Not present, trace, mild.
|
Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit
|
Change From Baseline in Contrast Sensitivity (Log Score) for Part A
Time Frame: Baseline, Week 1, 4, 8, 12 weeks
|
Change from Baseline in contrast sensitivity over all 12 weeks log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E.
Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values.
Lower log scores equals lower contrast sensitivity and worse outcome.
Higher log scores mean higher contrast sensitivity and better outcome.
For 3cpd, range is 0.7-2.08;
6 cpd: 0.91-2.29;
12 cpd: 0.61-1.99;
18cpd: 0.17-1.55,
unless no gratings were visible.
If no gratings were visible, .3
log was subtracted from the lowest score for 3, 6, and 12cpd.
For 18cpd .01
log was used, or essentially 100% contrast.
|
Baseline, Week 1, 4, 8, 12 weeks
|
Contrast Sensitivity for Part B; By-subject Data
Time Frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
|
Contrast Sensitivity log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E by-subject data, Part B. Part A is listed separately.
Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values.
Lower log scores equals lower contrast sensitivity and worse outcome.
Higher log scores mean higher contrast sensitivity and better outcome.
For 3cpd, range is 0.7-2.08;
6 cpd: 0.91-2.29;
12 cpd: 0.61-1.99;
18cpd: 0.17-1.55,
unless no gratings were visible.
If no gratings were visible, .3
log was subtracted from the lowest score for 3, 6, and 12cpd.
For 18cpd .01
log was used, or essentially 100% contrast.
|
Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Raizman, MD, Ophthalmic Consultants of Boston
- Principal Investigator: Edward Holland, MD, Cincinnati Eye Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2016
Primary Completion (Actual)
March 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
December 20, 2015
First Submitted That Met QC Criteria
January 10, 2016
First Posted (Estimate)
January 12, 2016
Study Record Updates
Last Update Posted (Actual)
September 17, 2021
Last Update Submitted That Met QC Criteria
August 20, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPIFD-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fuchs' Corneal Endothelial Dystrophy (FCED)
-
Kowa Research Institute, Inc.CompletedFuchs' Endothelial Corneal DystrophyUnited States, Australia, Germany, Spain, Denmark
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...UnknownFuchs' Corneal Endothelial DystrophyUnited States
-
Massachusetts Eye and Ear InfirmaryRecruitingFuchs' Endothelial Corneal DystrophyUnited States
-
EmmecellRecruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
State University of New York at BuffaloActive, not recruitingFuchs DystrophyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneKyoto University, Graduate School of MedicineCompletedFuchs Endothelial Corneal DystrophyFrance
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
-
Cornea Research Foundation of AmericaCompletedBullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyUnited States
-
Kowa Research Institute, Inc.RecruitingFuchs Endothelial Corneal DystrophyGermany, United States, Spain, Canada, United Kingdom, Denmark
Clinical Trials on Part A Elamipretide 1.0% Ophthalmic Solution
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
Herantis Pharma Plc.ORA, Inc.CompletedDry Eye SyndromeUnited States
-
Stealth BioTherapeutics Inc.CompletedLeber's Hereditary Optic NeuropathyUnited States
-
Silk Technologies, Ltd.Completed
-
Silk Technologies, Ltd.Completed
-
Rigel PharmaceuticalsCompletedKeratoconjunctivitis SiccaUnited States
-
VivaVision Biotech, IncRecruitingInflammationUnited States
-
Seinda Pharmaceutical Guangzhou CorporationCompleted
-
Bausch & Lomb IncorporatedCompletedAllergic ConjunctivitisUnited States
-
ONL TherapeuticsActive, not recruitingOpen Angle GlaucomaAustralia, New Zealand